Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$0.86
<$0.01(1.08%)
At close: 4:00 PM EDT
$0.86
<$0.01(1.08%)
Day’s Range― - ―
52-Week Range$0.57 - $6.70
Previous Close$0.92
Volume18.36K
Average Volume (3M)122.25K
Market Cap
$5.62M
Enterprise Value$1.30M
Total Cash (Recent Filing)$3.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield598.01%
Share Statistics
EPS (TTM)-3.64
Shares Outstanding6,622,794
10 Day Avg. Volume10,301
30 Day Avg. Volume122,252
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit3.62
Enterprise Value/Ebitda-0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Improving Revenue TractionRevenue growth indicates that BGMS is gaining commercial traction and expanding its operating base. If this improvement persists, a larger revenue platform could support better fixed-cost absorption and create a foundation for future operating leverage, although profitability has not yet followed.
Low Leverage And Positive EquityAn essentially debt-free balance sheet limits creditor pressure and avoids substantial interest obligations while the company works to improve operations. Positive equity also provides a stronger starting capital position than a highly leveraged structure, supporting flexibility over the next several quarters.
Strategic Shift To Fire SafetyThe move toward fire safety products represents a structural change in BGMS's business model rather than a temporary operating fluctuation. A clearer commercial focus and cost streamlining under new management could improve execution and establish a more durable revenue base.
Bears Say
Severe Operating UnprofitabilityBGMS remains far from a scalable cost structure, with operating losses exceeding revenue and substantial net losses despite improving sales. Persistently weak margins can consume capital, limit reinvestment capacity, and make future earnings highly dependent on achieving significant cost and revenue improvements.
Persistent Cash BurnNegative operating and free cash flow means the business is still consuming cash rather than funding itself through operations. Although the burn improved from 2025, continued cash usage keeps external funding needs elevated and could constrain investment or weaken financial flexibility before breakeven.
Material Dilution And Transaction RiskThe proposed combination creates substantial ownership dilution for existing shareholders if completed, while the securities offering demonstrates reliance on equity financing. These actions can reduce current holders' economic influence and make the future capital structure materially less favorable.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.57 and its highest was $6.70 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $5.62M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Nov 18, 2026 which is in 37 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on Aug 12, 2026. The company reported -$0.076 earnings per share for the quarter.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $36 which represents an annual dividend yield of 598.01%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 6,622,794 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$0.076 in its last earnings report. Following the earnings report the stock price went up 0.217%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
45.19% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
54.78% Public Companies and
Individual Investors